Aller au contenu principal
Accès ouvert déclaré 2025 article

Application of PDCA cycle management in the rational use of perioperative antimicrobial prophylaxis in orthopedic clean surgery

1Citations signalées, ce qui n’est pas une note de qualité
2Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: Optimal antimicrobial prophylaxis has been demonstrated to reduce the incidence of surgical site infections (SSIs). The PDCA cycle management approach has been extensively adopted in the healthcare industry. The objective of this study is to examine the impact of PDCA cycle management on the rational use of perioperative antimicrobial prophylaxis in orthopedic clean surgeries. METHODS: Following a thorough evaluation of the antibiotic prescription practices for patients undergoing orthopedic clean surgeries at the hospital during the initial three-month period of 2023, a series of pertinent measures were devised and initiated as a dynamic intervention from April 2023 to February 2024. The rationality of perioperative prophylactic antimicrobial use and clinical outcomes were compared before and after the intervention. RESULTS: The irrational use of perioperative prophylactic antibiotics was significantly reduced. It is mainly reflected in the utilization of surgical antibiotic prophylaxis [94.7% vs. 84.8%, p < 0.001, 95% CI (1.753,6.851)], inappropriate prophylaxis [68.7% vs. 47.3%, p < 0.001,95% CI (0.276,0.595)], unindicated prophylaxis [18.0% vs. 2.9%, p < 0.001,95% CI (0.045,0.273)], inappropriate drug selection [13.3% vs. 2.9%, p < 0.001, 95% CI (0.057,0.413)], and inappropriate intraoperative redosing [1.7% vs. 0%, p = 0.024,95% CI (0.964,0.996)]. In addition, the rate of inappropriate dosage [1.3% vs. 0%, p = 0.120, 95% CI (0.971,0.996)], inappropriate timing [3.9% vs. 1.7%, p = 0.146,95% CI (0.092,1.463)], and inappropriate postoperative antibiotic switching [0.4% vs. 0%, p = 0.494,95% CI (0.984,0.996)] were also decreased. However, the rate of inappropriate prophylaxis duration [42.1% vs. 42.3%, p = 0.965, 95% CI (0.680, 1.462)] and combination treatment [1.3% vs. 7.1%, p = 0.002, 95% CI (2.052, 23.292)] increased. With regard to clinical outcomes, the length of stay[15(10) to 13(7), p = 0.012, 95% CI(0.000,3.000)], hospitalization expenses[50244.96(53,376.00) to 41,539.92(31,809.94), p = 0.01, 95% CI (2157.160, 15,935.620)], medication costs[4326.215(3672.48) to 3272.17(2885.15), p < 0.001, 95% CI (498.170, 1745.440)], antibiotic costs [274.435(351.89) to 219.12(239.04), p = 0.004, 95% CI (19.920,119.520)], and other perioperative infections rates [46.3% to 26.4%, p < 0.001, 95% CI (1.427,4.090)] all decreased significantly after the intervention. CONCLUSION: The PDCA cycle management strategy was found to be an effective method of optimizing the rational use of perioperative prophylactic antibiotics and clinical outcomes in orthopedic clean surgeries. Nevertheless, this approach is encumbered by time-sensitive limitations, and its intervention effects are challenging to sustain over an extended period, thus necessitating further refinement.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Application of PDCA cycle management in the rational use of perioperative antimicrobial prophylaxis in orthopedic clean surgery
Date Crossref
25/11/2025
Éditeur
Springer Science and Business Media LLC
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

  • Chinese PLA General Hospital Department of Pharmacy pays non établi dans la notice
    Établissement de santé
  • Harbin Medical University Department of Pharmacology (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) pays non établi dans la notice
    Université ou école supérieure

Department of Pharmacy — Chinese PLA General Hospital et Department of Pharmacology (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China) — Harbin Medical University.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Surgical site infection preventionAntibiotic Use and ResistanceAntimicrobial agents and applications

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.